When the PRV system was originally proposed by David Ridley, Henry Grabowski and Jeffrey Moe in 2006 in their Health Affairs article Developing Drugs for Developing Countries, the worth of PRVs was estimated at $300 million. With the purchase of the PRV by AbbVie, that estimate has been surpassed, with the four (of six awarded) vouchers sold to date realising ever increasing prices. A little over a year ago, Sanofi and Regeneron Pharmaceuticals paid US$67.5 million to BioMarin Pharmaceuticals for their PRV, which has successfully been used to gain FDA approval for the PCSK9 cholesterol drug Praluent, ahead of Amgen’s competitor product. A few months later, Gilead Sciences went on to pay US$125 million to Knight Therapeutics for their PRV to advance the approval of Gileads’ new HIV drug, while Retrophin commanded $245 million from Sanofi when they sold their PRV earlier this year.

This news is encouraging at a time when Medicines Development for Global Health, in partnership with the Global Health Investment Fund and the World Health Organization Special Programme for Research and Training in Tropical Diseases, is working on the registration of moxidectin for the treatment of onchocerciasis, one of the PRV-eligible NTDs.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.